glp 1 prostate cancer May Patients Receiving GLP-1 Agonists Be at Lower Risk of Aggressiveness and Progression? Glucagon-like Peptide 1 Receptor Agonists

It has shown promise as a treatment of erectile dysfunction and autism, among other conditions

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) are also sometimes included with GLP1s, although they work a little differently

Clinical pharmacology studies show tirzepatide has a half-life of approximately 5 days, allowing for once-weekly dosing with sustained therapeutic effects (Frias et al., Diabetes Care, 2021)

Antioxid Redox Signal 38:599618 Che X, Brydges CR, Yu Y, Price A, Joshi S, Roy A, Lee B, Barupal DK, Cheng A, Palmer DM, Levine S, Peterson DL, Vernon SD, Bateman L, Hornig M, Montoya JG, Komaroff AL, Fiehn O, Lipkin WI (2022) Evidence for peroxisomal dysfunction and dysregulation of the CDP-choline pathway in myalgic encephalomyelitis/chronic fatigue syndrome

Preliminary findings from Virtas book of business indicate its prescribing solution drove transformative health outcomes and immediate business impact, including: Substantial reduction in GLP-1 utilization and corresponding costs Responsible Prescribing prevents ongoing GLP-1 use by over 50% among current GLP-1 users, lowering costs for payers

pharmacovigilance experts are monitoring for adverse signals beyond clinical trials